Communiqués Eagle Pharmaceuticals, Inc.

Actions

EGRX

US2697961082

Produits pharmaceutiques

Marché Fermé - OTC Markets 20:47:42 14/09/2026			Varia. 5j.	Varia. 1 janv.
1,285 ^USD	+696,65%		+70,20%	+83,57%

03/06	Elite Laboratories Inc, AbbVie Inc, Par Health USA LLC, Sunstar Americas Inc, eVenus Pharmaceutical Lab Inc, Navinta LLC, PTS Consulting LLC, Makro Technologies Inc, Eagle Pharmaceuticals Inc et CMC GMP LLC retirent l'homologation de 16 demandes d'abrégés de nouveaux médicaments (ANDA)	CI
14/01	Eagle Pharmaceuticals annonce la cession de Barhemsys	RE

Communiqués

09/04	Did Eagle Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?	PR
14/01	Eagle Pharmaceuticals Announces Divestiture of Barhemsys	AQ
24/12	HALPER SADEH LLC ENCOURAGES EAGLE PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS	PR
30/10/25	Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan	AQ
21/10/25	Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders	AQ
15/10/25	Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements	AQ
07/10/25	Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements	AQ
17/09/25	Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years	AQ
29/08/25	Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors	AQ
18/08/25	Eagle Pharmaceuticals Announces 2025 Annual Meeting Date	AQ
31/03/25	Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties	AQ
24/03/25	Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan	AQ
21/03/25	Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan	AQ
02/12/24	Eagle Pharmaceuticals : Corporate Action Form 8 K	PU
18/11/24	Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration	AQ
15/11/24	Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration	AQ
12/11/24	Eagle Pharmaceuticals : Appoints Christopher Krawtschuk as Chief Financial Officer Form 8 K	PU
12/11/24	Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer	AQ
31/10/24	EAGLE PHARMACEUTICALS : ADOPTS LIMITED DURATION STOCKHOLDER RIGHTS PLAN Form 8 K	PU
31/10/24	Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan	AQ
02/10/24	Eagle Pharmaceuticals : Non Reliance of Financial Report Form 8 K	PU
27/08/24	Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq	AQ
22/05/24	Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq	AQ
30/04/24	Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting	AQ
16/04/24	Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting	AQ